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ABSTRACT
In this study, ten new 5-substituted-3-[4,6-di(morpholine-4-yl)-1,3,5-triazine-2-yl]-1,3,5-thiadiazolium-2-thiolate 6(a–j) were
prepared via a five step procedure from the starting material 1,3,5-triazine (1). Structures of all synthesized compounds were
confirmed by spectral data and elemental analyses. Newly synthesized compounds were tested for their antibacterial and
antifungal activities against some important bacterial and fungal species. Some of the compounds were found to be moderately
active against the tested organisms.
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1. Introduction
Mesoionic compounds are one of the essential classes of
heterocycles because of their synthetic utilities and various
biological and synthetically applications.1,2 They have received
much attention and have been extensively studied because of
their unique structures, reaction behaviour and pharmaceutical
activities.3–5 1,3,4-Thiadiazolium mesoionics have been found to
possess potential applications in various fields of chemistry like
pharmaceutical, polymer, industrial, agriculture, coordination
chemistry, etc.6–10 1,3,4-Thiadiazolium-2-thiolates are one of the
important mesoionic compounds having good biological activi-
ties.11–13 s-Triazine is a six membered heterocycle consisting of
three nitrogen atoms and three carbon atoms alternately located
in the ring system. Several derivatives of s-triazine have exhibited
antibacterialactivities.14–18 In addition, they are also found
application as pharmaceutical products and herbicides.19,20
s-Triazine derivatives have also been applied as anti-HIV21,22,
anti-malarial 23,24 and anti-cancer25,26 agents. Jogul and Badami27
have synthesized various 4-[4-(2-sulphido-1,3,4- thiadia-
zolium)benzoyl]-1,3,4-thiadiazolium-2-thiolate derivatives and
some of these compounds were found to possess anti-tuber-
culosis activity and anti-bacterial activity, notably higher than
the activity of the reference drug used.
2. Results and Discussion
Synthesis of the compounds 6(a–j) has been carried out as
depicted in Fig. 1. 2-(4,6-Dimorpholin-4-yl-1,3,5-triazin-2-yl)
hydrazinecarbodithioic acid (5) was prepared from s-triazine (1)
in four steps. The two chlorine atoms of s-triazine ring were
replaced by morpholine group to give compound 3 which on
treatment with hydrazine hydrate, followed by reaction with
carbondisulfide in the presence of potassium hydroxide resulted
in the formation of compound 5. Cyclization of 2-(4,6-di-
morpholin-4-yl-1,3,5-triazin-2-yl)hydrazinecarbodithioic acid
(5) with various acid chlorides then gave 5-substituted-3-[4,6-
di(morpholine-4-yl)-1,3,5-triazine-2-yl]-1,3,5-thiadiazolium-2-
thiolates 6(a–j). All the synthesized compounds were character-
ized by their spectral data. The structure of compounds 6(a–j)
were established on the basis of elemental analysis and spectral
data. The IR spectra of compounds 6(a–j) showed a strong band
between 1150–1097 cm–1 for the C-O-C stretching of morpho-
line.28 The C=N stretching of the s-triazine ring was observed
around ~1530, ~1350 (weak) and ~760 cm–1;29–31 furthermore,
the bands at 1310–1328 cm–1 are attributed to C-S stretching
of thiadiazolium.27 Finally, the bands observed around
3485–3228 cm–1 and 3200 cm–1 due to NH3 stretching and NH
stretching of hydrazine group.27 The 1H-NMR spectra of
compounds 6(a–j) showed chemical shifts for the N-CH2 groups
of morpholine at ca. δ 2.56 and the O-CH2 groups at ca. δ 3.80. The
chemical shifts of the NH protons of the hydrazine group of
compound 4 were found upfield (δ ≈6.00 ppm) in comparison
with those of the chemical shift of hydrazinocarbonyl group
(δ ≈10.31 ppm), as reported in the literature,27 due to the effect of
electron withdrawing characteristics of carbonyl group. Finally,
the 13C-NMR spectra for compounds 6(a–j) showed signals
nearly ca. δ 164.5 for C-2 of the thiadiazole ring which was found
in good agreement with literature data.27
2.1 Antimicrobial Activity
All the synthesized compounds were screened for their
antibacterial activity against Gram-positive bacteria Staphylococ-
cus aureus, Streptococcus pyogenes and Gram-negative bacteria
Escherichia coli and Pseudomanas aeruginosa, as well as antifungal
activities against Candida albicans, Aspergillus niger and Asper-
gillus clavatus (Table 1). Preliminary antimicrobial testing was
carried out by the Microbroth dilution method.32 The reference
drugs used were gentamycin for antibacterial activity and
nystatin for antifungal activity. The activity of the samples and
the reference drugs was assayed under identical conditions.
From the table it can be seen that the 4-nitrophenyl and
2-chloro-5-nitrophenyl at position 5 of the thiadiazole ring
showed increasing activity in comparison with the rest of the
compounds against S. aureus and S. pyogenes, respectively.
Furthermore, the presence of methyl groups at this position on
the thiadiazole ring also increased the activity against E.coli
and P. aeruginosa. All the compounds were found to possess
moderate to poor activity against the fungal species in compari-
son with standard drug nystatin. The numerical values in Table 1
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show that the standard drugs were several times more effective
than synthesized compounds. In addition, compound 6i against
S. aureus, 6d against S. pyogenes, 6c against E.coli and P. aeruginosa
were found to be the most active in terms of bactericidal activity.
The rest of the compounds were found to exhibit moderate to
poor activity in comparison with the standard gentamycin. In
addition, all the compounds were found to possess moderate to
poor activity against the fungal species, in contrast with nystatin.
It can thus be concluded that the antibacterial and antifungal
activity of the compounds varies with a variation in substitution
on thiadiazole ring system.
3. Conclusion
Novel substituted 1,3,4-thiadiazolium-2-thiolates were syn-
thesized from s-triazine in good yields and were characterized
by spectral data and elemental analysis. This work highlights a
simple, interesting synthetic route for 1,3,4-thiadiazolium-
2-thiolate derivatives. Some of the compounds were effectively
active against tested organisms. This opens the door for further
evaluation of this class of compounds, in particular with the
aim of generating valuable data pertaining to structure–activity
relationships.
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Figure 1 Synthesis of 5-(substituted)-3-[4,6-di(morpholine-4-yl)-1,3,5-triazine-2-yl]-1,3,5-thiadiazolium-2-thiolates 6(a–j).
Table 1 Antibacterial and antifungal activity of compounds 6(a–j).
Compound Antibacterial Antifungal
Gram-positive Gram-negative
S. aureus S. pyogenes E. coli P. aeruginosa C. albicans A. niger A. clavatus
6a 500 500 250 250 1000 1000 1000
6b 500 500 200 250 1000 1000 1000
6c 500 500 100 100 1000 1000 1000
6d 500 200 500 200 500 1000 1000
6e 250 250 250 250 1000 1000 1000
6f 250 500 250 200 500 500 1000
6g 250 500 500 250 1000 500 500
6h 500 250 200 250 500 500 1000
6i 200 250 500 500 1000 1000 500
6j 500 250 500 250 500 500 1000
Gentamycin 0.25 0.5 0.05 1.0 – – –
Nystatin – – – – 100 100 100
4. Experimental
4.1. General Procedures
Melting points were determined by open capillary method
and were found uncorrected. The IR spectra were recorded on
Shimadzu FTIR instrument using KBr pellets. NMR spectra
were recorded on Brucker Avance II NMR at 400 MHz, using
TMS as the internal standard and DMSO-d6 as solvent. TLC was
performed on E-Merck pre-coated 60 F254 plates and the spots
were rendered visible by exposure to UV light. Samples were
routinely purified by crystallization from ethanol and checked
by TLC. 5-(Substituted)-3-(4,6-dimorpholin-4-yl-1,3,5-
triazin-2-yl)-1,3,4-thiadiazolium-2-thiolate 6(a–j) were synthe-
sized by the synthetic route described in Fig.  1.
4.2. Preparation of 2,4-Dichloro-6-morpholino-4-yl-1,3,5-
triazine (2)33,34
To a stirred solution of cyanuric chloride (0.01 mol) in acetone
(15 mL) at 0–5 °C, the solution of morpholine (0.01 mol) in
acetone (5 mL) was added and the pH was maintained neutral
by the addition of 10 % sodium carbonate solution. The stirring
was continued at 0–5 °C for four hours. After the completion of
the reaction the stirring was stopped and the solution was
poured into crushed ice. The solid product thus obtained was
filtered and dried. The crude product was purified by crystalli-
zation from absolute alcohol to get title compound. Yield 72 %.
M.p. 137–139 °C.
IR (KBr): 1510, 1350, 1114, 820 cm–1; 1H NMR (400 MHz,
DMSO-d6): δ 3.58–3.93 (m, 8H, CH2 morpholine);
13C NMR
(40 MHz, DMSO-d6): δ 171.1, 162.4, 47.7, 69.0. Anal (%) for
C7H8ON4Cl2. Calcd. C, 35.77; H, 3.43; N, 23.83. Found: C, 35.85; H,
3.38; N, 23.93.
4.3. Preparation of 2-Chloro-4,6-dimorpholino-4-yl-1,3,5-
triazine (3)33,34
To a stirred solution of 2,4-dichloro-6-morpholino-4yl-1,3,5-
triazine (0.01 mol) in acetone (10 mL) at 30–35 °C, the solution of
morpholine (0.01 mol) in acetone (5 mL) was added drop-wise
maintaining the temperature at 35°C. The pH was adjusted to
neutral by the addition of 10 % sodium carbonate solution. The
temperature was gradually raised to 45 °C during two hours.
After completion of the reaction, the resultant content was
poured into ice-cold water. The solid product obtained was
filtered and dried. The crude product was purified by crystalli-
zation from absolute alcohol to get the title compound. Yield
68 %. M.p. 164–166 °C.
IR (KBr): 1505, 1356, 1120, 806 cm–1; 1H NMR (400 MHz,
DMSO-d6): δ 2.95 (s, 2H, CH2), 3.47 (t, 8H, NCH2 morpholine,
J = 4.7 Hz), 4.25 (t, 8H, OCH2 morpholine, J = 4.6 Hz);
13C NMR
(40 MHz, DMSO-d6): δ 46.8, 68.8, 171.1, 163.2. Anal (%) for
C11H16O2N5Cl. Calcd. C, 46.24; H, 5.64; N, 24.51. Found: C, 46.31;
H, 5.56; N, 24.62.
4.4. Preparation of 2-Hydrazino-4,6-dimorpholino-4-yl-1,3,5-
triazine (4)34
A mixture of 2-chloro-4,6-dimorpholino-4-yl-1,3,5-triazine
(0.01 mol) and hydrazine hydrate (0.012 mol) in ethanol (25 mL)
was refluxed in a water bath. The temperature was gradually
raised to 80–90 °C during three hours. The pH was adjusted
neutral by the addition of 10 % aqueous sodium carbonate
solution. After the completion of reaction, the refluxed content
was added to cold water. The solid product obtained was filtered
and dried. The crude product was purified by crystallization
from absolute alcohol. Yield 74 %. M.p. 183–185 °C.
IR (KBr): 3485–3228, 1512, 1353, 1110 cm–1; 1H NMR (400 MHz,
DMSO-d6): δ 3.63 (t, 8H, NCH2 morpholine, J = 4.7 Hz), 4.22 (t,
8H, OCH2 morpholine, J = 4.6 Hz), 4.79 (s, 2H, NH-NH2), 6.00 (s,
2H, NH-NH2);
13C NMR (40 MHz, DMSO-d6): δ 47.8, 68.9, 170.0,
164.4. Anal (%) for C11H19O2N7 . Calcd. C, 46.96; H, 6.81; N, 34.85.
Found: C, 47.07; H, 6.89; N, 34.90.
4.5. Preparation of the Potassium Salt of 2-(4,6-Dimorpholin-
4-yl-1,3,5-triazin-2-yl) Hydrazinecarbodithioic Acid (5)27
To a stirred mixture of 2-hydrazino-4,6-dimorpholino-4-yl-
1,3,5-triazine (0.01 mol) and potassium hydroxide (0.01 mol) in
absolute alcohol (15 mL), in which carbon disulphide (0.02 mol)
was added drop wise and the mixture was stirred for one hour at
room temperature. The yellowish colored precipitate was
treated with ether (25 mL). The solid that separated was filtered,
washed with ether and dried. M.p. > 300 °C. IR (KBr): 3200, 1518,
1347, 1186, 1103. 1H NMR (400 MHz, DMSO-d6): δ 3.63 (t, 8H,
NCH2 morpholine, J = 4.7 Hz), 4.36 (t, 8H, OCH2 morpholine, J =
4.6 Hz) 10.21 (s, 2H, NH-NH); 13C NMR (40 MHz, DMSO-d6):
δ 46.7, 69.3, 165.9, 173.5, 201.3. Anal (%) for C12H18O2N7S2K. Calcd.
C, 36.44; H, 4.59; N, 24.79. Found: C, 36.58; H, 4.45 ; N, 24.86 .
4.6. Preparation of 5-(Substituted)-3-(4,6-dimorpholin-4-yl-
1,3,5-triazin-2-yl)-1,3,4-thiadiazolium-2-thiolates 6(a–j)
General procedure: To a stirred solution of potassium salt of
2-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl) hydrazinecarbo-
dithioic acid (0.01 mol) in water was added the appropriate acid
chloride (0.012 mol). The reaction mixture was stirred for 2 hours
at room temperature. The pale yellow solid that separated was
filtered, washed repeatedly with ice-cold water and recrystal-
lized from ethanol.
Spectral data of 5-(substituted)-3-(4,6-dimorpholin-4-yl-1,3,5-
triazin-2-yl)-1,3,4-thiadiazolium-2-thiolates 6(a–j):
5-(Phenyl)-3-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-1,3,4-
thiadiazolium-2-thiolate 6a: Yield: 76 %; m.p. 171–173 °C. IR
(KBr): 1560, 1375, 1318, 1110, 760 cm–1; 1H NMR (400 MHz,
DMSO-d6): δ 3.40 (t, 8H, NCH2 morpholine, J = 4.7 Hz), 4.05 (t,
8H, OCH2 morpholine, J = 4.6 Hz), 7.52–8.12 (m, 5H, Ar-H);
13C NMR (40 MHz, DMSO-d6): δ 45.2, 68.0, 127.7, 131.1, 131.9,
137.6, 140.4, 141.5, 165.0, 170.3; Anal. (%) for C19H21O2N7S2. Calcd.
C, 51.45; H, 4.77; N, 22.11. Found: C, 51.52; H, 4.68; N, 22.23.
5-(Chloromethyl)-3-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-
1,3,4-thiadiazolium-2-thiolate 6b: Yield: 72 %; m.p. 132–134 °C.
IR (KBr): 2950, 2884, 1530, 1370, 1315, 1118, 876, 787 cm–1; 1H NMR
(400 MHz, DMSO-d6): δ 3.00 (s, 2H, CH2), 3.46 (t, 8H, NCH2
morpholine, J = 4.7 Hz), 4.14 (t, 8H, OCH2 morpholine, J =
4.6 Hz); 13C NMR (40 MHz, DMSO-d6): δ 44.6, 51.7, 67.9, 137.4,
139.4, 164.7, 170.5. Anal. (%) for C14H18O2N7ClS2. Calcd. C, 40.43;
H, 4.36; N, 23.57. Found: C, 40.56; H, 4.42; N, 23.48.
5-(Methyl)-3-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-1,3,4-
thiadiazolium-2-thiolate 6c: IR (KBr): Yield: 78 %; m.p.
190–192 °C. 2975, 2886, 1495, 1352, 1325, 1104, 810 cm–1; 1H NMR
(400 MHz, DMSO-d6): δ 1.82 (s, 3H, CH3), 3.50 (t, 8H, NCH2
morpholine, J = 4.7 Hz), 4.21 (t, 8H, OCH2 morpholine, J =
4.6 Hz); 13C NMR (40 MHz, DMSO-d6): δ 20.7, 45.8, 68.1, 137.6,
140.3, 165.1, 170.5. Anal. (%) for C14H19O2N7S2. Calcd. C, 44.08;
H, 5.02; N,  25.70. Found C, 44.21; H, 5.18; N, 25.63.
5-(4-Nitrophenyl)-3-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-
1,3,4-thiadiazolium-2-thiolate6d: Yield: 70 %; m.p. 137–139 °C.
IR (KBr): 1538, 1477, 1380, 1360, 1312,1150, 783 cm–1; 1H NMR
(400 MHz, DMSO-d6): δ 3.42 (t, 8H, NCH2 morpholine, J =
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4.7 Hz), 4.05 (t, 8H, OCH2 morpholine, J = 4.6 Hz), 8.13–8.32 (m,
4H, Ar-H); 13C NMR (40 MHz, DMSO-d6): δ 45.3, 68.3, 125.9,
133.4, 137.7, 140.6, 145.5, 148.2, 164.2, 170.6. Anal. (%) for
C19H20O4N8S2. Calcd. C, 46.71; H, 4.13; N, 22.94. Found: C, 46.60;
H, 4.20; N, 22.86.
5-(2-Nitrophenyl)-3-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-
1,3,4-thiadiazolium-2-thiolate 6e: Yield: 68%; m.p. 148–150 °C.
IR (KBr): 1521, 1483, 1367, 1348, 1318, 1134, 768 cm–1; 1H NMR
(400 MHz, DMSO-d6): δ 3.50 (t, 8H, NCH2 morpholine, J =
4.7 Hz), 4.25 (t, 8H, OCH2 morpholine, J = 4.6 Hz), 7.84–8.42 (m,
4H, Ar-H); 13C NMR (40 MHz, DMSO-d6): δ 45.0, 68.3, 127.7,
130.5, 131.1, 137.5, 135.8, 137.8, 140.3, 152.1, 165.5, 170.6. Anal. (%)
for C19H20O4N8S2. Calcd. C, 46.71; H, 4.13; N, 22.94. Found:
C, 46.63; H, 4.02; N, 22.87.
5-(3-Nitrophenyl)-3-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-
1,3,4-thiadiazolium-2-thiolate 6f: Yield: 73 %; m.p. 159–161 °C.
IR (KBr): 1538, 1443, 1354, 1328, 1110, 811 cm–1; 1H NMR
(400 MHz, DMSO-d6): δ 3.64 (t, 8H, NCH2 morpholin, J = 4.7 Hz),
4.12 (t, 8H, OCH2 morpholin, J = 4.6 Hz), 7.86–8.38 (m, 4H, Ar-H);
13C NMR (40 MHz, DMSO-d6): δ 45.3, 68.3, 122.7, 127.3, 132.1,
137.5, 138.00, 140.6, 141.3, 151.3, 165.8, 170.5. Anal. (%) for
C19H20O4N8S2. Calcd. C, 46.71; H, 4.13; N, 22.94. Found: C, 46.60;
H, 4.25; N, 22.83.
5-(4-Methoxy-3-nitrophenyl)-3-(4,6-dimorpholin-4-yl-1,3,5-
triazin-2-yl)-1,3,4-thiadiazolium-2-thiolate 6g: Yield: 66 %;
m.p. 145–147 °C. IR (KBr): 2920, 2863, 1567, 1483, 1348, 1310, 1323,
1278, 1134, 1097, 768 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 3.48
(t, 8H, NCH2 morpholine, J = 4.7 Hz), 4.26 (s, 3H, OCH3), 4.30 (t,
8H, OCH2 morpholine, J = 4.6 Hz), 7.26 (d, 1H, Ar-H), 8.35 (d, 1H,
Ar-H), 8.96 (d, 1H, Ar-H); 13C NMR (40 MHz, DMSO-d6): δ 45.6,
58.3, 68.3, 115.4, 127.6, 135.9, 136.8, 137.2, 140.7, 141.7, 152.6, 164.8,
170.7. Anal. (%) for C20H22O5N8S2. Calcd. C, 46.32; H, 4.28;
N, 21.61. Found: C, 46.39; H, 4.38; N, 21.55.
5-(4-Chlorophenyl)-3-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-
1,3,4-thiadiazolium-2-thiolate6h: Yield: 65 %; m.p. 152–154 °C.
IR (KBr): 1436, 1353, 1313, 1109, 874, 805 cm–1; 1H NMR (400 MHz,
DMSO-d6): δ 3.52 (t, 8H, NCH2 morpholine, J = 4.7 Hz), 4.21 (t,
8H, OCH2 morpholine, J = 4.6 Hz), 7.53–7.71 (m, 4H, Ar-H);
13C NMR (40 MHz, DMSO-d6): δ 45.9, 68.1, 131.1, 132.7, 133.8,
137.9, 139.6, 140.7, 165.1, 170.6. Anal. (%) C19H20O2N7S2Cl. for
Calcd. C, 47.74; H, 4.22; N, 20.51. Found: C, 47.66; H, 4.34;
N, 20.64.
5-(2-Chloro-5-nitrophenyl)-3-(4,6-dimorpholin-4-yl-1,3,5-
triazin-2-yl)-1,3,4-thiadiazolium-2-thiolate6i: Yield: 72 %; m.p.
140–142 °C. IR (KBr): 1552, 1406, 1342, 1104, 1374, 1319, 883,
820 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 3.60 (t, 8H, NCH2
morpholine, J = 4.7 Hz), 4.00 (t, 8H, OCH2 morpholine, J =
4.6 Hz), 7.93 (d, 1H, Ar-H), 8.54 (d, 1H, Ar-H), 8.76 (d, 1H, Ar-H);
13C NMR (40 MHz, DMSO-d6): δ 45.4, 68.5, 126.5, 127.4, 135.9,
134.3, 137.7, 140.6, 141.5, 150.4, 165.4, 170.6. Anal. (%) for
C19H19O4N8S2Cl. Calcd. C, 43.63; H, 3.66; N, 21.43. Found: C,
43.59; H, 3.72; N, 21.29.
5-(4-Chloro-3-nitrophenyl)-3-(4,6-dimorpholin-4-yl-1,3,5-
triazin-2-yl)-1,3,4-thiadiazolium-2-thiolate6j: Yield: 76 %; m.p.
136–138 °C. IR (KBr): 1545, 1415, 1369, 1343, 1310, 1117, 1054,
828 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 3.53 (t, 8H, NCH2
morpholine, J = 4.7 Hz), 4.12 (t, 8H, OCH2 morpholine, J =
4.6 Hz), 7.95 (d, 1H, Ar-H, J = 7.9 Hz), 8.32 (d, 1H, Ar-H, J =
7.9 Hz), 8.83 (d, 1H, Ar-H, J= 7.9 Hz); 13C NMR (40 MHz,
DMSO-d6): δ 45.8, 68.4, 126.6, 128.5, 135.9, 137.3, 137.7, 140.3,
141.0, 150.4, 164.4, 170.6. Anal. (%) for C19H19O4N8S2Cl.Calcd. C,
43.63; H, 3.66; N, 21.43. Found: C, 43.59; H, 3.72; N, 21.29.
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